TWEEDLE TIMES—Stocks continued to roar yesterday as Nvidia became the first $4T company and President Trump blanketed planet Earth with ass-chapping letters to all the world’s leaders. The President’s literary prose came into question due to Poor Punctuation with TOO …
aTyr Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading maintained a Buy rating on the stock and has a $22.00 price target. Soumit Roy has given his Buy rating due …
It’s all you can pick atop Monteagle Mountain. And that’s about the only real newsworthy thing that’s happening today. Nvidia being the first $4T company on the planet. Pshhh.🥱
Everyone here knows I’ve been in a particular trade and playing things aggressively for nearly two years now. But as this trade matures and we move closer to the stock’s catalyst, I’ve struggled with where to go next. Should I …
What opportunity looks like after investors lose 90% in a biotech recession (2022-2023). Were CountryDumbs greedy when the whole damn world was fearful?👍
Stories. In the course of a lifetime, people will pay thousands of dollars to be entertained by the experiences and fantasies of others, but yet, most will blow their time here on this earth without being a willing participant in …
TWEEDLE TIMES—Stocks are poised to rally this month under a new August extension for blanket tariffs. The Volatility Index (VIX) remained mute yesterday at 17 as the market largely looked past ongoing tariff chatter from the White House—a positive sign …
The CountryDumb experiment was never intended to be the daily bread of a small city, yet this community has grown three times larger than my own county’s entire population. I don’t mind. Hell, I don’t care how many people read …
America is about to be great again, or at least that’s what Treasury Secretary Scott Bessent would like us all to think. What we do know for certain, is America is about to be stimulated again! But don’t worry about …
The only thing this tells me is that ATYR is going to move violently when the Phase 3 Efzofitimod trial data drops this quarter, which is expected sometime after Labor Day. It’s encouraging to see this stock begin to ripen, …